Skip to main content
    C

    China Pharma Holdings Inc (CPHI)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • AMEX

    $0.52
    -0.04 (-7.47%)

    Market Cap: $22.29M

    Last updated: Nov 17, 2026 at 10:59 AM ET

    China Pharma Holdings Inc (CPHI) Financials: Revenue, Profit and Cash Flow

    Updated Aug 14, 2026. Financial statements from company filings, amounts in US dollars.

    China Pharma Holdings reported revenue of $4.14M for the fiscal year ended Dec 31, 2025, down 8.5% from the year before. That year, net income was -$3.19M with a net margin of -76.9%, operating cash flow was $148.26K and free cash flow was $88.94K. The quarter ended Jun 30, 2026 had revenue of $948.34K and net income of -$1.46M.

    Revenue and Margins

    The operating margin was -78.2% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue fell from $15.57M, a compound annual decline of 13.7%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$4.14M-8.5%-3.2%-78.2%-76.9%
    Dec 2024$4.53M-35.4%-43.8%-101.3%-104.6%
    Dec 2023$7.01M-13.5%-4.0%-39.2%-43.9%
    Dec 2022$8.10M-15.9%-6.1%-43.8%-49.0%
    Dec 2021$9.64M-11.3%6.3%-29.7%-35.3%
    Dec 2020$10.87M-0.5%18.0%-23.7%-26.4%
    Dec 2019$10.92M-11.4%13.6%-186.8%-189.5%
    Dec 2018$12.33M-6.7%11.1%-84.7%-87.2%
    Dec 2017$13.21M-15.1%18.7%-141.4%-145.9%
    Dec 2016$15.57MN/A20.7%-52.4%-59.0%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$4.14M$4.53M$7.01M$8.10M$9.64M$10.87M$10.92M$12.33M$13.21M$15.57M
    Cost of revenue$4.28M$6.51M$7.29M$8.60M$9.04M$8.91M$9.44M$10.96M$10.74M$12.35M
    Gross profit-$131.95K-$1.99M-$281.08K-$493.92K$604.49K$1.95M$1.48M$1.37M$2.47M$3.22M
    Research and development$129.34K$283.94K$240.08K$185.86K$318.96K$377.96K$229.64K$172.38K$90.47K$365.97K
    Operating income-$3.24M-$4.59M-$2.75M-$3.55M-$2.86M-$2.58M-$20.41M-$10.45M-$18.68M-$8.16M
    Net income-$3.19M-$4.74M-$3.08M-$3.97M-$3.40M-$2.87M-$20.70M-$10.75M-$19.28M-$9.18M
    EBITDA-$1.66M-$1.97M$1.83K-$848.44K$477.31K$101.18K-$17.48M-$7.19M-$15.39M-$5.08M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$948.34K$983.54K$1.23M$756.22K$1.03M$1.14M$1.13M$1.10M$924.94K$1.37M$2.15M$1.80M
    Gross profit$83.57K$285.49K$152.81K-$59.65K-$89.04K-$136.06K-$160.59K-$519.65K-$1.02M-$290.02K-$75.11K-$233.19K
    Operating income-$1.43M-$1.12M-$1.20M-$628.14K-$652.12K-$758.62K-$1.20M-$1.09M-$1.39M-$916.05K-$1.18M-$713.54K
    Net income-$1.46M-$1.14M-$1.22M-$651.48K-$528.37K-$785.57K-$1.22M-$1.12M-$1.44M-$955.89K-$1.23M-$777.60K
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, short-term debt of $3.41M exceeded cash and equivalents by $3.07M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$31.00M$14.89M$16.47M$17.78M$22.65M$21.12M$22.24M$45.38M$59.95M$78.52M
    Current assets$2.35M$3.27M$6.00M$5.96M$9.09M$5.32M$5.58M$8.75M$12.29M$17.52M
    Cash and equivalents$345.11K$626.88K$1.42M$2.03M$4.86M$957.65K$1.07M$1.19M$2.03M$2.67M
    Total liabilities$8.26M$7.14M$9.01M$13.49M$16.63M$13.11M$13.00M$15.18M$16.88M$19.61M
    Short-term debt$3.41M$2.16M$3.10M$6.24M$4.33M$2.04M$0$3.46M$3.02M$2.53M
    Long-term debtN/A$1.39M$1.41M$0$5.25M$904.23K$0$4.36M$6.92M$1.44M
    Shareholder equity$22.74M$7.75M$7.45M$4.29M$6.02M$8.00M$9.24M$30.20M$43.07M$58.91M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$44.71M$45.14M$31.00M$15.80M$13.77M$14.22M$14.89M$13.47M$14.26M$16.19M$16.47M$15.35M
    Total liabilities$8.53M$8.12M$8.26M$7.49M$7.30M$7.25M$7.14M$6.94M$6.85M$7.90M$9.01M$9.24M
    Cash and equivalents$304.87K$168.47K$345.11K$267.63K$625.03K$412.69K$626.88K$718.69K$739.34K$838.88K$1.42M$1.37M
    Shareholder equity$36.18M$37.02M$22.74M$8.31M$6.46M$6.97M$7.75M$6.53M$7.41M$8.29M$7.45M$6.11M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 60.0% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$148.26K-$406.06K-$699.69K-$409.55K-$249.84K-$42.26K$608.31K$1.88M$841.22K$2.90M
    Capital expenditures$59.32K$38.41K$11.52K$401.96K$438.06K$867.31K$136.00K$51.15K$136.48K$193.40K
    Free cash flow$88.94K-$444.47K-$711.20K-$811.51K-$687.89K-$909.57K$472.31K$1.83M$704.74K$2.70M
    Investing cash flow-$137.25K-$291.72K-$11.52K-$401.96K-$438.06K-$867.31K-$136.00K-$51.15K-$136.48K-$193.40K
    Financing cash flow-$294.03K-$33.78K$73.14K-$1.77M$4.60M$624.18K-$1.73M-$1.98M-$1.48M-$6.02M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$32.83K-$55.29K$151.99K-$236.99K$274.31K-$73.68K$298.77K-$46.95K-$72.73K-$585.16K-$22.32K$1.01M
    Capital expendituresN/A$0$454$611$65$58.32K$19.55K$9.22K$28.09K$0$4.53K$67.45K
    Free cash flowN/A-$55.29K$151.54K-$237.60K$274.24K-$132.00K$279.23K-$56.17K-$100.81K-$585.16K-$26.85K$939.83K
    Last 12 quarters

    Frequently Asked Questions About CPHI

    What is China Pharma Holdings' annual revenue?

    China Pharma Holdings reported revenue of $4.14M for the fiscal year ended Dec 31, 2025.

    How fast is China Pharma Holdings' revenue growing?

    Revenue was down 8.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -20.0%.

    Is China Pharma Holdings profitable?

    No. China Pharma Holdings reported net income of -$3.19M for the fiscal year ended Dec 31, 2025, with a net margin of -76.9%.

    How much free cash flow does CPHI generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $148.26K minus capital expenditures of $59.32K produced free cash flow of $88.94K.

    How much debt does China Pharma Holdings have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $3.41M and cash and equivalents of $345.11K.